Screener
Relmada Therapeutics, Inc. RLMD Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055059
| Line item | Three months ended / March 31, 2026 | Three months ended / March 31, 2025 |
|---|---|---|
| Proceeds from issuance of common stock | 159,999,996 | - |
| Payment of fees for issuance of common stock | (3,360,000) | - |
| ATM Fees | (65,651) | - |
| Net cash provided by financing activities | 156,574,345 | - |
| Net increase/(decrease) in cash and cash equivalents | 6,279,860 | (2,707,320) |
| Cash and cash equivalents at beginning of the period | 3,496,540 | 3,857,026 |
| Cash and cash equivalents at end of the period | $9,776,400 | $1,149,706 |
| Non-cash investing and financing activities: |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Relmada Therapeutics, Inc.'s financing cash flow?
- Relmada Therapeutics, Inc. (RLMD) reported financing cash flow of $156.57M in Q1 2026.
- What is the long-term trend for Relmada Therapeutics, Inc.'s financing cash flow?
- Over 2 years (2021 to 2023), Relmada Therapeutics, Inc.'s financing cash flow has grown at a -97.7% compound annual growth rate (CAGR), from $187.94M to -$98.46K.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Relmada Therapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude